USPTO serial 79246377
OOCUITY
Reviewed by CopyMark Law Group
Reg. 5809477Status 709
- Filing date
- Status date
- Registration date
- Jul 23, 2019
- Examiner
- O'BRIEN, JENNIFER LYNN
- Law office
- POST REGISTRATION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with OOCUITY?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Max Vern
Max Vern Amster, Rothstein & Ebenstein LLP405 Lexington AvenueNew York, NY 10174UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical products for medical use, namely, for the treatment of brain diseases and disorders; Pharmaceutical preparation for the diagnosis and treatment of brain diseases and disorders; Pharmaceutical preparation for medical use namely, for modifying the bioavailability of therapeutic agents; Pharmaceutical preparation for medical use namely, for the diagnosis and treatment of tumors; Pharmaceutical preparation for medical use particularly for the treatment of Parkinson's disease, Alzheimer's disease, epilepsy and all types of neurological and neuropsychiatric diseases and disorders; Pharmaceutical preparation for medical use namely, for [ the treatment of ] * treating the * symptoms of Parkinson's disease, symptoms of Alzheimer's disease, symptoms of epilepsy and symptoms [ relating to all kinds ] * related to any type * of neurological and neuropsychiatric [ diseases and disorders ] * disorders and diseases * ; Pharmaceutical preparation for the diagnosis and treatment of neurological disorders and diseases for use with deep brain stimulation, electrical transcranial stimulation, transcranial direct-current stimulation, transcranial magnetic stimulation, any form of electromagnetic stimulation in the nature of light, magnetic field, electric field, radio frequency or ultrasound stimulation; health * care * products, namely, pharmaceutical preparations for central nervous systems disorder treatment; radiological contrast substances for medical use; nanoparticles for medical use, namely, nanomaterial-based chemical preparations for medical and pharmaceutical purpose for the treatment of cancer, central nervous system disorder, cardiovascular, immunological, gastrointestinal, metabolic and infectious diseases ; Drug delivery agents in the form of nanomaterial-based preparation for the delivery of therapeutic agents; chemical reagents for medical use; bacteriological preparations for medical use; biological preparations for medical use, namely, for the treatment of cancer, central nervous system disorder, cardiovascular, immunological, gastrointestinal, metabolic and infectious diseases; enzymes for medical use; enzyme preparations for medical use; chemical preparations for medical or pharmaceutical use, namely, for the treatment of cancer, central nervous system disorders, cardiovascular, immunological, gastrointestinal, metabolic and infectious diseases; diagnostic products for medical use, namely, diagnostic preparations for medical purposes; drugs for medical use, namely, nanomaterial-based pharmaceutical preparation of active ingredients for the treatment of cancer, central nervous system disorders, cardiovascular, immunological, gastrointestinal, metabolic and infectious diseases; medicines for human medicine, namely, medical preparations for the treatment of cancer, central nervous system disorders, cardiovascular, immunological, gastrointestinal, metabolic and infectious diseases; tonics being medicines, namely, medicinal herbal preparations; antibiotics; antiseptics; chemico-pharmaceutical products, namely, chemical preparations for pharmaceutical or medical purposes, namely, for the treatment of cancer, central nervous system disorders, cardiovascular, immunological, gastrointestinal, metabolic and infectious diseases; pharmaceutical products, namely, pharmaceutical products for the treatment of cancer, central nervous system disorders, cardiovascular, immunological, gastrointestinal, metabolic and infectious diseases * for human use * ; dietetic substances for medical use, namely, dietetic foods adapted for medical purposes; remedies for human medicine, namely, natural remedy preparations for the treatment of gastrointestinal conditions, hormonal and chemical imbalances, and sleep disorder | SECTION 71 - CANCELLED | — |
| 010 | [ Surgical and medical apparatus and instruments especially for the diagnosis and treatment of tumors, namely, surgical apparatus and instruments for use in oncologic surgery, lasers for surgical and medical use, medical imaging devices, namely, ultrasound imaging apparatus, scanners and needle guides, and parts and fittings therefor; surgical and medical apparatus and instruments especially for monitoring and modifying metabolic functions, namely, heart rate monitoring apparatus, medical apparatus and instruments for monitoring vital signs, blood properties and respiratory events, devices for monitoring blood glucose for medical purposes; surgical and medical apparatus and instruments especially for the diagnosis and treatment of brain diseases and disorders, namely, medical imaging devices for the brain, medical devices for monitoring vital signs, blood properties and respiratory events, medical devices for monitoring brain's electrical activity, medical devices for monitoring cognitive and motor functions during neurosurgery, medical apparatus and instrument for diagnostic use, namely, apparatus for medical diagnostic testing in the fields of neurodegenerative diseases; surgical apparatus and instruments for deep brain stimulation, electrical transcranial stimulation, transcranial direct-current stimulation, transcranial magnetic stimulation, any form of electromagnetic stimulation, namely, light, magnetic field, electric field, radio frequency or ultrasound stimulation, namely, low level laser therapy, near-infrared light-emitting devices, electric devices for deep brain stimulation, wire coil devices for magnetic stimulation, scalp electrodes for transcranial direct-current stimulation, medical radiofrequency apparatus, medical ultrasound apparatus, electrical stimulation apparatus for scalp, nerves, skin, and muscles for physical therapy purposes; apparatus for the delivery of diagnostic or therapeutic agents, namely, medical apparatus and units for dosage, measuring and monitoring, namely, drug delivery devices and systems and organ oxygenation and perfusion apparatus; testing apparatus for medical use, namely, medical imaging devices for monitoring oxygen level in the brain, medical imaging devices for monitoring glucose level in the brain, medical imaging devices for monitoring proteins level in the brain, microdialysis devices for monitoring proteins level in the cerebrospinal fluid, medical devices for monitoring the brain's electrical activity; diagnostic apparatus for medical use, namely, medical diagnostic apparatus for testing the brain's electrical activity, oxygen level in the brain, glucose level in the brain, proteins level in the brain; Medical apparatus for the recording of electrical brain activity, namely, electrodes, electroencephalograph, micro-electrode arrays; apparatus for electrophysiology, namely, medical electrodes for patch-clamp devices, current-clamp devices, voltage-clamp devices, micro-electrode arrays devices; apparatus for neuronal modeling, namely, medical imaging apparatus incorporating medical imaging software and computational software sold as a unit therewith ] | SECTION 7(e) - CANCELLED | — |
| 042 | Scientific and technological services namely, scientific research and research and design in the field of nanomedicine in the nature of nanotechnology applied to medicine; biological research services; bacteriological research services; electrophysiological research; research in neuronal modeling; Testing, analysis and evaluation of service providers to determine conformity with established accreditation standards, namely, evaluations, estimates and research in scientific and technological fields provided by engineers and researchers; design and development of new products for third parties; technical project studies, namely, technical research in the field of pharmaceutical project studies; industrial analysis and research services in the field of biomedical research; chemical analysis; chemical research; chemistry services, namely, chemistry consultation; surveying, namely, conducting engineering surveys; research and development of new products for others; technical research in the field of pharmaceutical studies; research in the field of neuroscience; research in radio-biology; research in nanoscience and nanotechnology, especially applied to medicine | SECTION 71 - CANCELLED | — |
| 044 | Healthcare especially in the field of nanomedicine; medical services especially in the field of nanomedicine; hospital services; medical assistance; physiotherapy | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by NANOBIOTIX
- Other trademarks owned by NANOBIOTIX
- Other trademarks owned by NANOBIOTIX
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named OOCUITY
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 6, 2026 | INTR | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Feb 6, 2026 | C71T | CANCELLED SECTION 71 | — |
| Jul 23, 2024 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Mar 31, 2023 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Mar 31, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Mar 31, 2023 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Mar 31, 2023 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Mar 31, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 31, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Mar 31, 2023 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Jul 11, 2020 | INNA | INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE | — |
| Jun 23, 2020 | INPR | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Mar 9, 2020 | LIME | LIMITATION FROM THE IB EXAMINED AND ENTERED | — |
| Mar 7, 2020 | COC. | CORRECTION UNDER SECTION 7 - PROCESSED | — |
| Nov 22, 2019 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Nov 2, 2019 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Nov 2, 2019 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Nov 1, 2019 | LIMG | LIMITATION OF GOODS RECEIVED FROM IB | — |
| Oct 23, 2019 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Oct 17, 2019 | LIME | LIMITATION FROM THE IB EXAMINED AND ENTERED | — |
| Oct 16, 2019 | COC. | CORRECTION UNDER SECTION 7 - PROCESSED | — |
| Oct 16, 2019 | PLGL | ASSIGNED TO PARALEGAL | — |
| Jul 23, 2019 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| May 31, 2019 | LIMG | LIMITATION OF GOODS RECEIVED FROM IB | — |
| May 7, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 3, 2019 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Apr 17, 2019 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Apr 17, 2019 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Apr 17, 2019 | NPUB | NOTICE OF PUBLICATION | — |
| Mar 25, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 25, 2019 | CNEA | EXAMINERS AMENDMENT MAILED | — |
| Mar 22, 2019 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Mar 22, 2019 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Mar 15, 2019 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 15, 2019 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jan 25, 2019 | RFNP | REFUSAL PROCESSED BY IB | — |
| Jan 5, 2019 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jan 5, 2019 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Dec 20, 2018 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Dec 19, 2018 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 19, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 4, 2018 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Nov 30, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 29, 2018 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |